Experience of using human albumin solution 4·5% in 1195 therapeutic plasma exchange procedures

Transfusion Medicine

Volumn 20, Issue 4, 2010, Pages 244-249

  Pusey, C ^a   Dash, C ^b   Garrett, M ^c   Gascoigne, E ^b   Gesinde, M ^d   Gillanders, K ^b   Wallington, T ^d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b BIO PRODUCTS LABORATORY   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

adverse reactions; human albumin solution 4.5 ; Therapeutic plasma exchange

Indexed keywords

HUMAN ALBUMIN; SERUM ALBUMIN;

ADULT; AGED; ANAPHYLAXIS; APHERESIS; ARTICLE; BLOOD DONOR; BLOOD PRESSURE; BRONCHOSPASM; CHILD; CONTROLLED STUDY; DIZZINESS; DYSPNEA; FEMALE; FEVER; HEALTH SURVEY; HEART RATE; HUMAN; HYPOXIA; MAJOR CLINICAL STUDY; MALE; PAIN; PLASMAPHERESIS; RIGOR; SCHOOL CHILD; TACHYCARDIA; UNITED KINGDOM; UNITED STATES; VITAL SIGN; VOMITING; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSIS RELATED GROUP; DRUG HYPERSENSITIVITY; HEMODYNAMICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DIAGNOSIS-RELATED GROUPS; DRUG HYPERSENSITIVITY; FEMALE; FEVER; GREAT BRITAIN; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; UNITED STATES; YOUNG ADULT;

EID: 77954378563     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/j.1365-3148.2010.00999.x     Document Type: Article

References (13)

1. Basic-Jukic, N., Kes, P., Glavas-Boras, S., Brunetta, B., Bubic-Filipi, L. Puretic, Z. (2005) Complications of therapeutic plasma exchange: experience with 4857 treatments. Therapeutic Apheresis and Dialysis, 9, 391 395.
2. Boughton, B., Pusey, C., Kyei-Mensah, P., Watts, M. Marshall, C. (1993) Celite adsorbed human albumin may reduce febrile reactions in patients undergoing therapeutic plasma exchange. Transfusion Medicine, 1 (Suppl.), 35.
3. Committee for Medicinal Products for Human Use, Guideline on the Core SPC for Human Albumin Solution (CPMP/PhVWP/BPWG/2231/99 rev. 2), London 17 November 2005.
4. European Pharmacopoeia Monograph for Human Albumin Solution [0255].
5. Kiprov, D., Golden, P., Rohe, R., Smith, S., Hofmann, J. Hunnicutt, J. (2001) ADRs associated with mobile therapeutic apheresis: analysis of 17,940 procedures. Journal of Clinical Apheresis, 16, 130 133.
6. Levy, J Pusey C.D. (2007) Plasma exchange. In: Comprehensive Clinical Nephrology (3rd edn) (eds Johnson, R.J. Feehally J. 1013 1020. Harcourt Publishers
7. McLeod, B. (2006) Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange. Best Practice and research. Clinical Haematology, 19, 157 167.
8. Mokrzycki, M.H. Kaplan, A.A. (1994) Therapeutic plasma exchange: complications and management. American Journal of Kidney Diseases, 23, 817 827.
9. Norda, R., Bérseus, O. Stegmayr, B. (2001) Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. Transfusion and Apheresis Science, 25, 33 41.
10. Shemin, D., Briggs, D. Greenan, M. (2007) Complications of therapeutic plasma exchange: a prospective study of 1727 procedures. Journal of Clinical Apheresis, 22, 270 276.
11. Summary of Product Characteristics, Zenalb 4.5 (a Human Albumin 4.5% Solution), Bio Products Laboratory, Dagger Lane, Elstree, Herts, WD6 3BX, September 1998.
12. Sutton, D.M., Nair, R.C., Rock, G. The Canadian Apheresis Study Group. (1989) Complications of plasma exchange. Transfusion, 29, 124 127.
13. ® 4·5) in therapeutic plasma exchange. Transfusion Medicine, 2 (Suppl.), 70.